Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial.

Clicks: 263
ID: 42756
2019
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
A randomized controlled noninferiority trial was conducted in HIV-infected patients receiving tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV) with virological suppression in a resource-limited setting. Switching to TDF/FTC/rilpivirine was noninferior to continuing TDF/FTC/EFV in terms of maintaining compete viral suppression at 24 weeks and provided better lipid profiles and fewer central nervous system adverse effects.
Reference Key
wiriyatanakorn2019switchingopen Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Wiriyatanakorn, Sirichai;Sungkanuparph, Somnuek;
Journal Open forum infectious diseases
Year 2019
DOI
10.1093/ofid/ofz297
URL
Keywords
randomized controlled trial antiretroviral therapy switching efavirenz rilpivirine

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.